文献速递先天性心脏病外科

婴儿心脏移植中供受体体重不匹配增加与等待时间缩短相关且不增加并发症或死亡率

Increasing donor-recipient weight mismatch in infant heart transplantation is associated with shorter waitlist duration and no increased morbidity or mortality.
PubMed 文献 · Eur J Cardiothorac Surg · 2023-01-01

基于美国器官共享联合网络数据库2007至2020年1392例婴儿心脏移植数据,按供受体体重比(DRWR)分为≤1.0、1.0-2.0和>2.0三组,发现DRWR>2.0组等待时间显著缩短(33 vs 50天,P<0.1),围术期并发症及1年、5年生存率组间无显著差异,且DRWR分组与手术死亡无关。

要点

  • DRWR>2.0组等待时间显著短于其他组(33 vs 50天,P<0.1)。
  • DRWR>2.0组围术期并发症及1年、5年生存率与其他组无显著差异。
  • DRWR分组与手术死亡无关,移植前ECMO是唯一显著因素(OR=4.400)。

核心结论

  • 婴儿接受DRWR>2.0(最高达4.1)的心脏移植等待时间缩短,围术期并发症及手术或晚期死亡率无显著增加。

研究设计与样本

  • 利用美国器官共享联合网络数据库的回顾性队列研究,纳入2007年至2020年间1392例接受心脏移植的婴儿,按DRWR分为A组(≤1.0,n=239,17%)、B组(1.0-2.0,n=947,68%)和C组(>2.0,n=206,15%)。

主要发现

  • DRWR范围为0.5至4.1。
  • C组患者更可能接受机械通气、ABO血型不合心脏及更长供体缺血时间。
  • 等待时间C组显著短于其他组(33 vs 50天,P<0.1)。
  • 早期结局A、B、C组分别为:手术死亡(6%、4%、3%,P=0.29)、原发性移植物功能障碍(5%、3%、3%,P=0.30)、肾功能衰竭(10%、7%、7%,P=0.42)和卒中(3%、4%、1%,P=0.36)。
  • DRWR分组与手术死亡无关:先天性心脏病患者OR=0.819(95%CI 0.523-1.282),心肌病患者OR=1.221(95%CI 0.780-1.912);移植前ECMO是唯一显著因素(OR=4.400,95%CI 2.761-7.010)。

临床怎么用

  • 作者认为,历史上因并发症(如高血压相关卒中、移植物功能障碍、死亡)而避免DRWR>2.0的做法目前在婴儿中不被支持,放宽DRWR接受标准可缩短心脏移植等待时间并可能改善等待期并发症和死亡率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Infants awaiting paediatric heart transplantation (PHT) experience long waitlist duration and high mortality due to donor shortage. Using the United Network for Organ Sharing database, we explored if increasing donor-recipient weight ratio (DRWR) >2.0 (recommended cutoff) was associated with adverse outcomes. METHODS: Between 2007 and 2020, 1392 infants received PHT. We divided cohort into 3 groups: A (DRWR ≤1.0, n = 239, 17%), B (DRWR 1.0-2.0, n = 947, 68%), C (DRWR >2.0, n = 206, 15%). Group characteristics and PHT outcomes were analysed. RESULTS: DRWR ranged between 0.5 and 4.1. Underlying pathology (congenital versus cardiomyopathy), gender, race, renal function and mechanical circulatory support were comparable between groups. Group C patients were more likely to be ventilated, to receive ABO blood group (ABO)-incompatible heart and to have longer donor ischaemic time. Waitlist duration was significantly shorter for group C (33 vs 50 days, P < 0.1). Early outcomes for groups A, B and C were the following (respectively): operative death (6%, 4%, 3%, P = 0.29), primary graft dysfunction (5%, 3%, 3%, P = 0.30), renal failure (10%, 7%, 7%, P = 0.42) and stroke (3%, 4%, 1%, P = 0.36). The DRWR group was not associated with operative death in either congenital (odds ratio (OR) = 0.819, 95% confidence interval (CI) = 0.523-1.282) or cardiomyopathy (OR = 1.221, 95% CI = 0.780-1.912) patients and only significant factor was pre-PHT extracorporeal membrane oxygenation (OR = 4.400, 95% CI = 2.761-7.010). Additionally, survival at 1 year (87%, 87%, 85%, P = 0.80) and 5 years (76%, 78%, 77%, P = 0.80) was comparable between the DRWR groups. CONCLUSIONS: Infants who received PHT with DRWR >2.0, up to 4.1, experienced shorter waitlist duration with no demonstrable increase in peri-transplant complications, operative or late mortality. Historic practice to avoid DRWR > 2.0 due to complications (e.g. hypertension-related stroke, graft dysfunction, death) is not currently supported in infants and stretching DRWR acceptance criteria would decrease PHT waitlist duration and potentially improve waitlist complications and mortality.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Alsoufi B, Kozik D, Lambert AN, et al. Increasing donor-recipient weight mismatch in infant heart transplantation is associated with shorter waitlist duration and no increased morbidity or mortality. Eur J Cardiothorac Surg. 2023. PMID: 37701977. doi:10.1093/ejcts/ezad316

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。